PsilodexMedication × psilocybin
Your list , 0 items
General prescriptions
Brand names
Betapace, Betapace AF, Sotylize
Reviewed 2026-10-04

Sotalol

A beta-blocking antiarrhythmic, FDA-approved for life-threatening ventricular arrhythmias and to maintain normal rhythm in symptomatic atrial fibrillation or flutter.

psilodex.org/m/sotalol · data v2026.10.05

Clinical contraindication
None listed
No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence
No psilocybin data
Half-life
~12 h
Approximate, in adults. Source under Interaction below.
Named in state rules?
Not namedColorado Condition rules (3)
Not namedOregon
PendingNew Mexico
Cite asPsilodex, “Sotalol”, v2026.10.05. psilodex.org/m/sotalol

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for
  • Life-threatening ventricular arrhythmias
  • Maintenance of normal sinus rhythm in highly symptomatic atrial fibrillation or atrial flutter
Sources [1]
Other safety

Boxed warning: life-threatening ventricular tachycardia with QT prolongation; treatment is started or restarted in a facility with continuous ECG monitoring and cardiac resuscitation.

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

ND

It may dampen psilocybin's temporary rise in heart rate and blood pressure. Also, it affects heart rhythm, and stopping it suddenly can worsen heart problems.

Detail Sotalol is a beta-blocker that lowers heart rate and blood pressure, so it may lessen psilocybin's transient rise in heart rate and blood pressure. No psilocybin data exist. Also, sotalol prolongs the QT interval (a heart-rhythm measure). Stopping a beta-blocker abruptly can worsen angina (chest pain) or cause a heart attack. Sources [1]

Human data with psilocybin
No psilocybin data; based on how it works
Half-life
~12 h (FDA label, checked 2026-10-04) Prolonged with kidney impairment (up to 69 h in anuria).
Evidence types on this record
No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

4 listed · counted on reports
Withdrawal or rebound if stopped abruptly
Stopping suddenly can cause withdrawal or a rebound of symptoms. Sources [1]
Lowers blood pressure or causes orthostasis
Lowers blood pressure, or causes a drop on standing (orthostasis) that can bring dizziness or fainting. Sources [1]
QT-prolonging
Lengthens the QT interval on an ECG, a measure of the heart’s electrical recovery between beats. A long QT raises the risk of a dangerous heart rhythm, more so with other QT-prolonging drugs or low potassium or magnesium. Sources [1]
Hypoglycemia risk
Can cause low blood sugar, especially if meals are missed or delayed. Sources [1]

03 State rules

Plain-language summary · official text governs
CO4 CCR 755-1
Not namedCondition rules (3)

No provision names this medication or its class.

Colorado · checked 2026-10-04
OROAR 333-333
Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04
NM7.35.3 NMAC (proposed)
Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

  • Cardiovascular disease likely
    • CO 2.5(A)(2) · Clinical Facilitator licensees
    • CO 6.16(F)(2)(a) · Facilitators without a clinical facilitator license
    • CO 6.16(F)(1) · All licensees

05 Sources

1
  1. BETAPACE / BETAPACE AF (sotalol hydrochloride) tablets (Legacy Pharma) · FDA label (DailyMed) — revised 2024-12 | QT-prolonging: Boxed Warning: Life-Threatening Proarrhythmia "Sotalol can cause life-threatening ventricular tachycardia associated with QT interval prolongation." | Lowers blood pressure or causes orthostasis: 5.3 Hypotension "Sotalol produces significant reductions in both systolic and diastolic blood pressures and may result in hypotension." | Withdrawal or rebound if stopped abruptly: 5.5 Cardiac Ischemia after Abrupt Discontinuation "Following abrupt cessation of therapy with beta-adrenergic blockers, exacerbations of angina pectoris and myocardial infarction may occur." | "The mean elimination half-life of sotalol is 12 hours." | Warnings and Precautions: 5.7 Effects on Blood Sugar: "Beta-blockers may prevent early warning signs of hypoglycemia, such as tachycardia, and increase the risk for severe or prolonged hypoglycemia at any time during treatment"

Record history

  • v2026.10.02First published.
  • 2026-10-04Last reviewed against its sources.

Report an error in this record →

Before you startTerms 2026-10-01

What Psilodex is, and isn't.

  1. 01Psilodex summarizes published evidence and public state rules. It does not decide whether you can safely use psilocybin or take part in services, and it is not medical advice.
  2. 02Psilodex presents information only. Do not stop or change a medication without talking with the prescriber. Bring the report to them.
  3. 03Your searches and list stay in this browser and are not sent to us. Opening a medication's page is an ordinary web request, so our hosting providers see which page was opened. What we can and can't see.

In an emergency, call 911. For a mental health crisis, call or text 988. Full terms and privacy.